Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of long-acting hGH (MOD-4023) in adults with growth hormone deficiency
2013-000830-37Phase 3Completed
- Sponsor
- OPKO Biologics
- Start
- May 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in growth hormone deficiency (GHD) comparing MOD-4023 with Placebo (2 arms). Primary endpoint: Change in trunk fat mass from baseline to 26 weeks. Started May 2013; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2013-000830-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000830-37.